CHOSA to present new Platin-DRP® data at ASCO 2026
24th April 2026 - CHOSA Oncology AB (“CHOSA” or the “Company”) today announces that new data on its Drug Response Predictor, Platin-DRP®, has been selected for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2026, taking place May 29 - June 2, 2026, at McCormick Place, Chicago, Illinois, USA.
The Company will present two scientific abstracts highlighting the potential clinical utility of Platin-DRP® across multiple cancer settings and technologies:
- mRNA-based profile to predict platinum sensitivity in NSCLC assessed by NanoString – a translational analysis of the Phase III SPLENDOUR trial conducted in collaboration with the leading international groups; ETOP/EORTC.
- Taxane and platinum combination prediction of pathologic complete response in breast cancer – an analysis from the I-SPY2 study evaluating the combined use of Platin-DRP® and a taxane predictor to refine treatment selection in the neoadjuvant setting.
The abstracts will be presented at ASCO 2026, and full data will be made available in connection with the respective poster and/or presentation sessions.
Platin-DRP® is a gene expression–based biomarker designed to predict which patients are most likely to benefit from platinum-based chemotherapy, including cisplatin and carboplatin, which remain a backbone of treatment across multiple cancer types.
Further details on presentation timing and session information will be announced ahead of the conference.
For more information please contact:
Peter Buhl Jensen, CEO
peter@chosa.bio
+ 45 21 60 89 22
About CHOSA Oncology AB
CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression–based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes and optimize treatment selection in cancer care.
Background
Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer therapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Platin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer.
As previously announced, CHOSA is also exploring the predictive potential of Platin-DRP in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort and potentially confirm its utility across both drugs. Future research will also aim to determine whether Platin-DRP can predict the effectiveness of platinum drugs combined with PD-1/L1 inhibitors. CHOSA Oncology AB is an oncology biotechnology company led by an experienced international team with expertise in oncology, drug development, clinical trials, regulatory affairs, and business development. CHOSA intends to enter into partnership or sublicensing agreements for LiPlaCis® and the DRP®.
About ETOP IBCSG Partners Foundation
The ETOP IBCSG Partners Foundation is a not-for-profit international academic research organization based in Berne, Switzerland. Established on July 1, 2021, through the merger of the European Thoracic Oncology Platform (ETOP) and the International Breast Cancer Study Group (IBCSG), the foundation aims to promote scientific exchange and advance cancer research, particularly in thoracic and breast cancers.
The foundation's mission is to answer questions that improve patients' lives, with a vision of enhancing scientific exchange on a global scale. It achieves this by implementing and promoting clinical and translational research studies, fostering collaboration among international investigators, and organizing educational events such as annual meetings and residential workshops.
About EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
About Platin-DRP, a test to predict if cisplatin treatment is likely to be successful
CHOSA is focused on its Platin-DRP® drug response predictor, to which it holds worldwide rights. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Breast: Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP® responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well. Lung: Platin-DRP has also demonstrated its ability to predict the benefit of adjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. This is where Platin-DRP may become a game changer, particularly in newer neoadjuvant settings where immunotherapy has shown high efficacy in combination with platinum doublets. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%¹. In 2026 CHOSA in collaboration with key opinion leaders in lung cancer showed the Platin-DRP in advanced clearly separated the patient with a sensitive cancer from a platin resistant tumor with a median survival of 16.9 months in the former group vs only 5.5 months in the latter2.
Immunotherapy Cisplatin and carboplatin have often been shown to activate the immune system, potentially making “cold” tumours more susceptible to PD-1 inhibitors. This synergy may be important not only in lung cancer, but also in breast cancer, bladder cancer and head & neck cancer. In the growing PD-1 inhibitor market, CHOSA’s approach may offer the ability to predict whether platin can provide synergy with PD-1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume 11, Supplement 3, 106773, April 2026
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.